RxDoctor Payments Data

Theresa Harrington Stukus

Adult Health · Fairfax, VANPI 1104801844

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Gilead accounts for 64.5% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $19,968, more than ten times the $781 reported in 2021. Among adult health clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,954in general payments, 2019–2025

Across 102 payments — averaging $391.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$26K
  • Pfizer$13K
  • Novartis$1K
  • Genentech USA, Inc.$93
  • Beone Medicines USA, Inc.$78
  • Merck$47
  • plus $153 from 6 others

What the payments were for

  • Consulting fees$6,41016%
  • Speaking & faculty fees$21,51154%
  • Travel & lodging$9,06623%
  • Food & beverage$1,8525%
  • Other$1,1153%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,954 in reported general payments places this provider in the 95th percentile of 368 adult health providers in Virginia.

See all adult health providers in Virginia

Medicare billing

Part B allowed, 2024
$10,418
Medicare patients
92
Services billed
115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KisqaliRibociclib Succinate26$407,171
VerzenioAbemaciclib16$217,443
LynparzaOlaparib12$199,710
IbrancePalbociclib11$173,771
Letrozole65$1,590
Anastrozole52$1,165
Minoxidil15$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali$1,246$407,17126 claims
Lilly USA, LLCVerzenio$20$217,44316 claims
AstraZenecaLynparza$36$199,71012 claims
PfizerIbrance$12,563$173,77111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 368 adult health providers in Virginia.

Other adult health in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →